Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Connect Biopharma Holdings (CNTB) Non-Current Assets (2023 - 2025)

Connect Biopharma Holdings (CNTB) has disclosed Non-Current Assets for 3 consecutive years, with $5.1 million as the latest value for Q4 2025.

  • Quarterly Non-Current Assets rose 19.04% to $5.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $19.8 million through Dec 2025, changed N/A year-over-year, with the annual reading at $5.1 million for FY2025, 19.04% up from the prior year.
  • Non-Current Assets hit $5.1 million in Q4 2025 for Connect Biopharma Holdings, up from $4.8 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $5.1 million in Q4 2025 to a low of $4.3 million in Q4 2024.
  • Historically, Non-Current Assets has averaged $4.8 million across 3 years, with a median of $4.9 million in 2023.
  • Biggest five-year swings in Non-Current Assets: decreased 12.15% in 2024 and later increased 19.04% in 2025.
  • Year by year, Non-Current Assets stood at $4.9 million in 2023, then decreased by 12.15% to $4.3 million in 2024, then rose by 19.04% to $5.1 million in 2025.
  • Business Quant data shows Non-Current Assets for CNTB at $5.1 million in Q4 2025, $4.8 million in Q3 2025, and $5.0 million in Q2 2025.